我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 AbbVie, Inc.
相关临床试验
1741
1522 进行中
药物批准
118
批准总数
监管机构
6
监管机构数
成立时间
N/A
招募中
156
9.0%
撤回
9
0.5%
进行中（未招募）
1519
87.3%
已完成
54
3.1%
尚未招募
3
0.2%
NMPA
National Medical Products Administration
17
EMA
European Medicines Agency
40
PHILIPPINES
Philippines FDA
SFDA
Saudi Food and Drug Authority
2
NPRA
National Pharmaceutical Regulatory Agency
4
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
52
- AbbVie Deutschland GmbH & Co. KG is conducting two separate first-in-human Phase 1 studies evaluating ABBV-525, a MALT1 inhibitor, and ABBV-101, a BTK degrader, for relapsed/refractory B-cell non-Hodgkin's lymphoma. - ABBV-525 targets the MALT1 protein that helps cancer cells survive and grow, while ABBV-101 represents a novel BTK degrader approach that removes BTK proteins rather than simply inhibiting them. - The ABBV-525 study will enroll approximately 150 participants worldwide over 64 months, while the ABBV-101 study will include approximately 188 patients over 60 months. - Both oral therapies aim to address unmet medical needs for patients whose B-cell malignancies have relapsed or become refractory to current treatments.
